补肺健脾汤联合噻托溴铵治疗慢性阻塞性肺疾病的效果及对患者FVC、FEV_1、FEV_1/FVC 的影响
|
摘要
目的:观察补肺健脾汤联合噻托溴铵治疗慢性阻塞性肺疾病的效果及对患者FVC、FEV_1、FEV_1/FVC的影响。方法:选取2015年5月～2016年6月期间我院收治的慢性阻塞性肺疾病患者78例,依据数字表法随机分为对照组和研究组,对照组采用噻托溴铵治疗,研究组采用补肺健脾汤联合噻托溴铵治疗,对比观察两组患者的治疗效果及对患者FVC、FEV_1、FEV_1/FVC的影响。结果:通过采用不同的治疗方法,治疗前两组患者的动脉血气指标水平没有明显的差异(P>0.05),治疗完成后研究组患者的PaO_2、a/APO_2、PaCO_2改善情况均明显优于对照组(P<0.05);治疗前两组患者的肺功能没有明显的差异(P>0.05),治疗完成后研究组患者的FVC、FEV_1、FEV_1/FVC均明显高于对照组(P<0.05);研究组和对照组的治疗有效率分别为94.9%、71.8%,存在的明显差异(P<0.05);治疗前两组患者的中医症状积分和生活质量评分没有明显的差异(P>0.05),治疗完成后研究组患者的中医症状积分和生活质量评分均明显低于对照组(P<0.05)。结论:采用补肺健脾汤联合噻托溴铵治疗慢性阻塞性肺疾病,可以有效改善患者的动脉血气分析指标以及肺功能,增强患者的免疫力,提高治疗效果,值得推广和应用。
Objective:To analyze the clinical effect of Bufei Jianpi Decoction combined with Tiotropium Bromide and its impact on the FVC,FEV1 and FEV1/FVC for COPD(chronic obstructive pulmonary disease) patients.Methods:78 COPD patients treated from May 2015 to June 2016 in our hospital were selected.The subjects were randomly divided into two groups.The controlled group took Tiotropium Bromide,the study group took the combined therapy of Bufei Jianpi Decoction and Tiotropium Bromide.The clinical effect as well as the index of FVC,FEV1 and FEV1/FVC for two groups were observed.Results:Before treatment,the arterial blood gas indicators for the two groups were not significantly different(P > 0.05).After treatment,the index of PaO_2,a/APO_2 and PaCO_2 for the study group were significantly better than the controlled group(P < 0.05).Before treatment,the pulmonary function for the two groups was not significantly different(P > 0.05).After treatment,the index of FVC,FEV1 and FEV1/FVC for the study group were significantly higher than the controlled group(P < 0.05).The clinical effective rate of the study group(94.9%) was significantly higher than the controlled group(71.8%)(P < 0.05).Before treatment,the TCM symptom scores and life quality for the two groups were not significantly different(P > 0.05).After treatment,the TCM symptom scores and life quality for the study group were significantly lower than the controlled group(P < 0.05).Conclusion:For COPD patients,the combined therapy of Bufei Jianpi Decoction combined with Tiotropium Bromide can efficiently improve the arterial blood gas indicators,pulmonary function,immune function and clinical effective rate.It is worthy of clinical promotion and application.
Objective:To analyze the clinical effect of Bufei Jianpi Decoction combined with Tiotropium Bromide and its impact on the FVC,FEV1 and FEV1/FVC for COPD(chronic obstructive pulmonary disease) patients.Methods:78 COPD patients treated from May 2015 to June 2016 in our hospital were selected.The subjects were randomly divided into two groups.The controlled group took Tiotropium Bromide,the study group took the combined therapy of Bufei Jianpi Decoction and Tiotropium Bromide.The clinical effect as well as the index of FVC,FEV1 and FEV1/FVC for two groups were observed.Results:Before treatment,the arterial blood gas indicators for the two groups were not significantly different(P > 0.05).After treatment,the index of PaO_2,a/APO_2 and PaCO_2 for the study group were significantly better than the controlled group(P < 0.05).Before treatment,the pulmonary function for the two groups was not significantly different(P > 0.05).After treatment,the index of FVC,FEV1 and FEV1/FVC for the study group were significantly higher than the controlled group(P < 0.05).The clinical effective rate of the study group(94.9%) was significantly higher than the controlled group(71.8%)(P < 0.05).Before treatment,the TCM symptom scores and life quality for the two groups were not significantly different(P > 0.05).After treatment,the TCM symptom scores and life quality for the study group were significantly lower than the controlled group(P < 0.05).Conclusion:For COPD patients,the combined therapy of Bufei Jianpi Decoction combined with Tiotropium Bromide can efficiently improve the arterial blood gas indicators,pulmonary function,immune function and clinical effective rate.It is worthy of clinical promotion and application.
引文
[1]周蓉.噻托溴铵对稳定期慢性阻塞性肺疾病患者血清细胞因子水平及肺功能的影响[J].临床肺科杂志,2016,21(08):1413~1416
[2]吴娟.孟鲁司特联合噻托溴铵对慢性阻塞性肺疾病患者肺功能、免疫功能及炎性因子的影响研究[J].实用心脑肺血管病杂志,2016,24(12):213~218
[3]中华医学会呼吸病学分会慢性阻塞性肺疾病分组.慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8~17
[4]Represasrepresas C,Fernándezvillar A,Ruanoravi?a A,et al.Screening for Chronic Obstructive Pulmonary Disease:Validity and Reliability of a Portable Device in Non-Specialized Healthcare Settings[J].Plos One,2016,11(1):e0145571~e0145586
[5]张凡.噻托溴铵粉联合布地奈德福莫特罗粉维持治疗COPD的临床效果观察[J].中国临床研究,2015,28(08):1030~1032
[6]王艳,史玉红,李圣,等.沙美特罗联合噻托溴铵对慢性阻塞性肺疾病患者血清MMP-2、MMP-9及IL-8水平的影响[J].现代生物医学进展,2017,17(1):145~147
[7]Ha Youn L,Mi C S,Jinwoo L,et al.Effect of tiotropium on lung function decline in early-stage of chronic obstructive pulmonary disease patients:propensity score-matched analysis of real-world data[J].International Journal of Chronic Obstructive Pulmonary Disease,2015,10(1):2185~92
[8]郭俊华,黄四云,李建国.噻托溴铵联合小剂量茶碱治疗稳定期中重度慢性阻塞性肺疾病的效果观察[J].中国医药,2015,10(8):1126~1130
[9]王万征,安军.噻托溴铵对稳定期慢性阻塞性肺疾病患者临床疗效及相关血清标志物水平的影响[J].中国慢性病预防与控制,2017,25(5):358~360
[10]彭楠,路遥,赵晶,等.慢性阻塞性肺疾病肺气虚证肺容积成像定量分析与症状积分分级的研究[J].北京中医药大学学报,2016,39(5):424~428
[11]Panahi Y,Ghanei M,Behzadi M,et al.Investigation of the efficacy of generic and brand-name tiotropium bromide in the management of chronic obstructive pulmonary disease:A randomized comparative trial[J].Saudi Pharmaceutical Journal,2016,24(2):147~152
[12]孙志芬,张媚霞,曲桂红,等.噻托溴铵治疗慢性阻塞性肺疾病稳定期的临床疗效及对血清白介素18、肿瘤坏死因子α、基质金属蛋白酶9水平的影响研究[J].实用心脑肺血管病杂志,2016,24(8):50~53
[13]Plesner L L,Warming P E,Nielsen T L,et al.Chronic obstructive pulmonary disease in patients with end-stage kidney disease on hemodialysis[J].Hemodialysis International,2016,20(1):68~77
[14]解春霞,刘敏,江芳超,等.骨疏康颗粒治疗稳定期慢性阻塞性肺疾病合并骨质疏松症的疗效观察[J].中医药导报,2017,2(02):104~106
[15]宋丽萍,向平超.噻托溴铵联合舒利迭雾化吸入治疗对中重度慢性阻塞性肺疾病患者肺功能状况及预后的影响[J].实用临床医药杂志,2017,21(13):22~25
[16]Condreay L,Huang L,Harris E,et al.Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease[J].Respiratory Medicine,2016,114:123~126
[17]宋丽芹,索丹,石雪颖,等.噻托溴铵结合无创通气对慢性阻塞性肺疾病稳定期患者肺功能的影响[J].中国慢性病预防与控制,2015,23(2):141~143
[18]Park J H,Lee J K,Heo E Y,et al.The effect of obesity on patients with mild chronic obstructive pulmonary disease:results from KN-HANES 2010 to 2012[J].International Journal of Chronic Obstructive Pulmonary Disease,2017,12:757~763
[19]郑国峰,李慧,魏娇娜,等.噻托溴铵辅治老年慢性阻塞性肺疾病疗效及对肺功能、TNF-α、IL-6的影响[J].疑难病杂志,2017,2(3):230~233
[20]李琳,杨为伟.宣肺清痰饮治疗痰热壅肺型慢性阻塞性肺疾病急性加重期60例疗效观察[J].中医药导报,2016,3(17):96~97
[2]吴娟.孟鲁司特联合噻托溴铵对慢性阻塞性肺疾病患者肺功能、免疫功能及炎性因子的影响研究[J].实用心脑肺血管病杂志,2016,24(12):213~218
[3]中华医学会呼吸病学分会慢性阻塞性肺疾病分组.慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8~17
[4]Represasrepresas C,Fernándezvillar A,Ruanoravi?a A,et al.Screening for Chronic Obstructive Pulmonary Disease:Validity and Reliability of a Portable Device in Non-Specialized Healthcare Settings[J].Plos One,2016,11(1):e0145571~e0145586
[5]张凡.噻托溴铵粉联合布地奈德福莫特罗粉维持治疗COPD的临床效果观察[J].中国临床研究,2015,28(08):1030~1032
[6]王艳,史玉红,李圣,等.沙美特罗联合噻托溴铵对慢性阻塞性肺疾病患者血清MMP-2、MMP-9及IL-8水平的影响[J].现代生物医学进展,2017,17(1):145~147
[7]Ha Youn L,Mi C S,Jinwoo L,et al.Effect of tiotropium on lung function decline in early-stage of chronic obstructive pulmonary disease patients:propensity score-matched analysis of real-world data[J].International Journal of Chronic Obstructive Pulmonary Disease,2015,10(1):2185~92
[8]郭俊华,黄四云,李建国.噻托溴铵联合小剂量茶碱治疗稳定期中重度慢性阻塞性肺疾病的效果观察[J].中国医药,2015,10(8):1126~1130
[9]王万征,安军.噻托溴铵对稳定期慢性阻塞性肺疾病患者临床疗效及相关血清标志物水平的影响[J].中国慢性病预防与控制,2017,25(5):358~360
[10]彭楠,路遥,赵晶,等.慢性阻塞性肺疾病肺气虚证肺容积成像定量分析与症状积分分级的研究[J].北京中医药大学学报,2016,39(5):424~428
[11]Panahi Y,Ghanei M,Behzadi M,et al.Investigation of the efficacy of generic and brand-name tiotropium bromide in the management of chronic obstructive pulmonary disease:A randomized comparative trial[J].Saudi Pharmaceutical Journal,2016,24(2):147~152
[12]孙志芬,张媚霞,曲桂红,等.噻托溴铵治疗慢性阻塞性肺疾病稳定期的临床疗效及对血清白介素18、肿瘤坏死因子α、基质金属蛋白酶9水平的影响研究[J].实用心脑肺血管病杂志,2016,24(8):50~53
[13]Plesner L L,Warming P E,Nielsen T L,et al.Chronic obstructive pulmonary disease in patients with end-stage kidney disease on hemodialysis[J].Hemodialysis International,2016,20(1):68~77
[14]解春霞,刘敏,江芳超,等.骨疏康颗粒治疗稳定期慢性阻塞性肺疾病合并骨质疏松症的疗效观察[J].中医药导报,2017,2(02):104~106
[15]宋丽萍,向平超.噻托溴铵联合舒利迭雾化吸入治疗对中重度慢性阻塞性肺疾病患者肺功能状况及预后的影响[J].实用临床医药杂志,2017,21(13):22~25
[16]Condreay L,Huang L,Harris E,et al.Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease[J].Respiratory Medicine,2016,114:123~126
[17]宋丽芹,索丹,石雪颖,等.噻托溴铵结合无创通气对慢性阻塞性肺疾病稳定期患者肺功能的影响[J].中国慢性病预防与控制,2015,23(2):141~143
[18]Park J H,Lee J K,Heo E Y,et al.The effect of obesity on patients with mild chronic obstructive pulmonary disease:results from KN-HANES 2010 to 2012[J].International Journal of Chronic Obstructive Pulmonary Disease,2017,12:757~763
[19]郑国峰,李慧,魏娇娜,等.噻托溴铵辅治老年慢性阻塞性肺疾病疗效及对肺功能、TNF-α、IL-6的影响[J].疑难病杂志,2017,2(3):230~233
[20]李琳,杨为伟.宣肺清痰饮治疗痰热壅肺型慢性阻塞性肺疾病急性加重期60例疗效观察[J].中医药导报,2016,3(17):96~97